{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:13:29Z","timestamp":1761520409731,"version":"build-2065373602"},"reference-count":93,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.clcc.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T19:49:09Z","timestamp":1661629749000},"page":"34-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic Therapy for Pancreatic Neuroendocrine Tumors"],"prefix":"10.1016","volume":"22","author":[{"given":"Margaret","family":"Wheless","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satya","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2022.08.003_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the united states","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clcc.2022.08.003_bib0002","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clcc.2022.08.003_bib0003","doi-asserted-by":"crossref","first-page":"312","DOI":"10.5732\/cjc.012.10295","article-title":"Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment","volume":"32","author":"Ro","year":"2013","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.clcc.2022.08.003_bib0004","first-page":"13","article-title":"Digestive well-differentiated grade 3 neuroendocrine tumors: current management and future directions","author":"Pellat","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clcc.2022.08.003_bib0005","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2022.08.003_bib0006","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2022.08.003_bib0007","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2022.08.003_bib0008","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"N.-T., phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2022.08.003_bib0009","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2022.08.003_bib0010","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2022.08.003_bib0011","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.2018.36.15_suppl.4004","article-title":"A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN cancer research group (E2211)","volume":"36","author":"Kunz","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clcc.2022.08.003_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194872","article-title":"Chemotherapy in neuroendocrine tumors","volume":"13","author":"Das","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clcc.2022.08.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.31744","article-title":"Comparison of design, eligibility, and outcomes of neuroendocrine neoplasm trials initiated from 2000 to 2009 vs 2010 to 2020","volume":"4","author":"Das","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clcc.2022.08.003_bib0014","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.soc.2019.11.004","article-title":"Medical management of gastroenteropancreatic neuroendocrine tumors","volume":"29","author":"Chandrasekharan","year":"2020","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.clcc.2022.08.003_bib0015","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2967\/jnumed.115.167007","article-title":"Comparison of the therapeutic response to treatment with a 177Lu-Labeled somatostatin receptor agonist and antagonist in preclinical models","volume":"57","author":"Dalm","year":"2016","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"10.1016\/j.clcc.2022.08.003_bib0016","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000080742","article-title":"Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment","volume":"80","author":"Reubi","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.clcc.2022.08.003_bib0017","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1158\/1078-0432.CCR-12-3458","article-title":"Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches","volume":"19","author":"Oberg","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2022.08.003_bib0018","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2022.08.003_bib0019","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/jco.2014.32.15_suppl.4107","article-title":"Progression-free survival (PFS) with lanreotide autogel\/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study","volume":"32","author":"Caplin","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"4_suppl","key":"10.1016\/j.clcc.2022.08.003_bib0020","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/jco.2016.34.4_suppl.434","article-title":"Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","volume":"34","author":"Phan","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clcc.2022.08.003_bib0021","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejca.2021.06.056","article-title":"Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results","volume":"157","author":"Pavel","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2022.08.003_bib0022","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2022.08.003_bib0023","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: first clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.clcc.2022.08.003_bib0024","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.clcc.2022.08.003_bib0025","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of","volume":"23","author":"Brabander","year":"2017","journal-title":"[Clin Cancer Res"},{"key":"10.1016\/j.clcc.2022.08.003_bib0026","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1053\/j.semnuclmed.2019.11.003","article-title":"Targeted \u03b1-Emitter therapy of neuroendocrine tumors","volume":"50","author":"Kunikowska","year":"2020","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.clcc.2022.08.003_bib0027","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","article-title":"(177)Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors","volume":"13","author":"Das","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2022.08.003_bib0028","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2021.39.15_suppl.4112","article-title":"Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors","volume":"39","author":"Strosberg","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clcc.2022.08.003_bib0029","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2018-01991","article-title":"Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors","volume":"104","author":"Zandee","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clcc.2022.08.003_bib0030","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","article-title":"Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours","volume":"41","author":"Ezziddin","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"year":"2018","series-title":"Afinitor (everolimus) [package insert]","key":"10.1016\/j.clcc.2022.08.003_bib0031"},{"key":"10.1016\/j.clcc.2022.08.003_bib0032","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","article-title":"Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway","volume":"28","author":"Missiaglia","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.08.003_bib0033","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","article-title":"Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study","volume":"34","author":"Yao","year":"2016","journal-title":"J Clin Oncol"},{"year":"2011","series-title":"Sutent (sunitinib malate) [package insert]","key":"10.1016\/j.clcc.2022.08.003_bib0034"},{"key":"10.1016\/j.clcc.2022.08.003_bib0035","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development","volume":"6","author":"Faivre","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clcc.2022.08.003_bib0036","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1158\/1078-0432.CCR-11-2105","article-title":"New strategies for advanced neuroendocrine tumors in the era of targeted therapy","volume":"18","author":"Dong","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2022.08.003_bib0037","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2022.08.003_bib0038","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.08.003_bib0039","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.08.003_bib0040","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2022.08.003_bib0041","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","article-title":"Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas","volume":"22","author":"Kouvaraki","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.08.003_bib0042","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000500862","article-title":"Temozolomide alone or combined with capecitabine for the treatment of advanced pancreatic neuroendocrine tumor","volume":"110","author":"de Mestier","year":"2020","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.clcc.2022.08.003_bib0043","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clcc.2022.08.003_bib0044","doi-asserted-by":"crossref","first-page":"29","DOI":"10.6004\/jnccn.2021.7017","article-title":"Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms","volume":"20","author":"Al-Toubah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clcc.2022.08.003_bib0045","doi-asserted-by":"crossref","first-page":"L17","DOI":"10.1530\/ERC-15-0543","article-title":"High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy","volume":"23","author":"Brieau","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clcc.2022.08.003_bib0046","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/onco.13611","article-title":"Efficacy of FOLFOX in patients with aggressive pancreatic neuroendocrine tumors after prior capecitabine\/temozolomide","volume":"26","author":"Al-Toubah","year":"2021","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.clcc.2022.08.003_bib0047","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1159\/000518650","article-title":"Oxaliplatin and 5-Fluorouracil in advanced well-differentiated digestive neuroendocrine tumors: a multicenter national retrospective study from the french group of endocrine tumors","volume":"112","author":"Girot","year":"2021","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.clcc.2022.08.003_bib0048","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/ERC-20-0482","article-title":"A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy","volume":"28","author":"Das","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clcc.2022.08.003_bib0049","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44170","article-title":"External validation of a clinical score for patients with neuroendocrine tumors under consideration for peptide receptor radionuclide therapy","volume":"5","author":"Das","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clcc.2022.08.003_bib0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/snuc.2002.31027","article-title":"Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings","volume":"32","author":"De Jong","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.clcc.2022.08.003_bib0051","first-page":"1841","article-title":"Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size","volume":"42","author":"de Jong","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clcc.2022.08.003_bib0052","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00259-018-3967-6","article-title":"PRRT genomic signature in blood for prediction of (177)Lu-octreotate efficacy","volume":"45","author":"Bodei","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clcc.2022.08.003_bib0053","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","article-title":"(2)(1)(3)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience","volume":"41","author":"Kratochwil","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clcc.2022.08.003_bib0054","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.121.263230","article-title":"Targeted alpha-emitter therapy with (212)Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-human, dose-escalation clinical trial","author":"Delpassand","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clcc.2022.08.003_bib0055","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with (225)Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to (177)Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clcc.2022.08.003_bib0056","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211018047","article-title":"Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors","volume":"13","author":"Das","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clcc.2022.08.003_bib0057","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1158\/1078-0432.CCR-19-1026","article-title":"Phase I trial of well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist (177)Lu-Satoreotide tetraxetan","volume":"25","author":"Reidy-Lagunes","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2022.08.003_bib0058","doi-asserted-by":"crossref","first-page":"C7","DOI":"10.1530\/ERC-19-0186","article-title":"The next generation of peptide receptor radionuclide therapy","volume":"26","author":"Brabander","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clcc.2022.08.003_bib0059","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.7150\/thno.15311","article-title":"Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib","volume":"6","author":"Nonnekens","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.clcc.2022.08.003_bib0060","doi-asserted-by":"crossref","first-page":"e4395","DOI":"10.1371\/journal.pone.0004395","article-title":"Activation of DNA-PK by ionizing radiation is mediated by protein phosphatase 6","volume":"4","author":"Mi","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2022.08.003_bib0061","series-title":"NANETS 2021 Symposium Abstracts","article-title":"ETCTN 10450: a Phase 1 Trial of Peposertib and Lutetium Lu 177 Dotatate in Well- differentiated Somatostatin Receptor- positive Neuroendocrine Tumors","author":"Chauhan","year":"2021"},{"key":"10.1016\/j.clcc.2022.08.003_bib0062","first-page":"56","article-title":"Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization","volume":"1","author":"Chapman","year":"2011","journal-title":"Front Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2022.08.003_bib0063","doi-asserted-by":"crossref","first-page":"TPS4660","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4660","article-title":"Etctn 10388: A phase I trial of triapine and lutetium Lu 177 dotatate in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","volume":"38","author":"Chauhan","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clcc.2022.08.003_bib0064","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40265-021-01489-y","article-title":"Surufatinib: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2022.08.003_bib0065","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1200\/JCO.2021.39.15_suppl.4114","article-title":"Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs)","volume":"39","author":"Paulson","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clcc.2022.08.003_bib0066","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9113655","article-title":"Emerging treatment options for gastroenteropancreatic neuroendocrine tumors","volume":"9","author":"Cives","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.clcc.2022.08.003_bib0067","unstructured":"Limited H M, BeiGene, surufatinib in combination with tislelizumab in subjects with advanced solid tumors. https:\/\/ClinicalTrials.gov\/show\/NCT04579757: 2021."},{"issue":"4_suppl","key":"10.1016\/j.clcc.2022.08.003_bib0068","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.2017.35.4_suppl.228","article-title":"Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET)","volume":"35","author":"Chan","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clcc.2022.08.003_bib0069","unstructured":"Testing cabozantinib in patients with advanced pancreatic neuroendocrine and carcinoid tumors. https:\/\/ClinicalTrials.gov\/show\/NCT03375320. 2022"},{"key":"10.1016\/j.clcc.2022.08.003_bib0070","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.08.003_bib0071","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1158\/1078-0432.CCR-19-3014","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study","volume":"26","author":"Strosberg","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2022.08.003_bib0072","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-20-0382","article-title":"Spartalizumab in metastatic, well\/poorly-differentiated neuroendocrine neoplasms","author":"Yao","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clcc.2022.08.003_bib0073","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2022.08.003_bib0074","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"4_suppl","key":"10.1016\/j.clcc.2022.08.003_bib0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2020.38.4_suppl.619","article-title":"A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs)","volume":"38","author":"Halperin","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clcc.2022.08.003_bib0076","unstructured":"Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors. https:\/\/ClinicalTrials.gov\/show\/NCT03290079. 2022"},{"key":"10.1016\/j.clcc.2022.08.003_bib0077","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1158\/1535-7163.MCT-19-0022","article-title":"Targeting the somatostatin receptor 2 with the miniaturized drug conjugate, PEN-221: a potent and novel therapeutic for the treatment of small cell lung cancer","volume":"18","author":"Whalen","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clcc.2022.08.003_bib0078","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1021\/acs.jmedchem.8b02036","article-title":"Discovery of an SSTR2-Targeting maytansinoid conjugate (PEN-221) with potent activity in vitro and in vivo","volume":"62","author":"White","year":"2019","journal-title":"J Med Chem"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2022.08.003_bib0079","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2018.36.15_suppl.4097","article-title":"First in human phase 1\/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results","volume":"36","author":"Johnson","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2022.08.003_bib0080","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2021.39.15_suppl.4110","article-title":"The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results","volume":"39","author":"Halperin","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clcc.2022.08.003_bib0081","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2022.08.003_bib0082","unstructured":"A study of XmAb\u00ae18087 in subjects with NET and GIST. https:\/\/ClinicalTrials.gov\/show\/NCT03411915. 2022"},{"key":"10.1016\/j.clcc.2022.08.003_bib0083","unstructured":"el-Rayes S P, V Villalobos, A Hendifar, et\u00a0al. Preliminary safety, PK\/PD, and antitumor activity of XmAb18087, an SSTR2 x CD3 bispecific antibody, in patients with advanced neuroendocrine tumors. NANETS 2020 Symposium Abstracts2020."},{"key":"10.1016\/j.clcc.2022.08.003_bib0084","article-title":"Molecular signatures and their clinical utility in pancreatic neuroendocrine tumors","volume":"11","author":"Chatani","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clcc.2022.08.003_bib0085","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s40265-021-01606-x","article-title":"Belzutifan: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2022.08.003_bib0086","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2021.39.15_suppl.4555","article-title":"Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC)","volume":"39","author":"Srinivasan","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clcc.2022.08.003_bib0087","unstructured":"Belzutifan\/MK-6482 for the treatment of advanced pheochromocytoma\/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET) (MK-6482-015). https:\/\/ClinicalTrials.gov\/show\/NCT04924075. 2022"},{"key":"10.1016\/j.clcc.2022.08.003_bib0088","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1158\/1078-0432.CCR-11-3264","article-title":"Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4\/cdk6","volume":"18","author":"Tang","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2022.08.003_bib0089","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-022-01251-x","article-title":"Cyclin-dependent kinases 4\/6 inhibitors in neuroendocrine neoplasms: from bench to bedside","author":"de Sousa","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clcc.2022.08.003_bib0090","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/MPA.0000000000000944","article-title":"Cell cycle protein expression in neuroendocrine tumors: ssociation of CDK4\/CDK6, CCND1, and phosphorylated retinoblastoma protein with proliferative index","volume":"46","author":"Shi","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.clcc.2022.08.003_bib0091","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1634\/theoncologist.2020-0033","article-title":"The PALBONET trial: a phase II study of palbociclib in metastatic grade 1 and 2 pancreatic neuroendocrine tumors (GETNE-1407)","volume":"25","author":"Grande","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2022.08.003_bib0092","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000463386","article-title":"The novel cyclin-dependent kinase 4\/6 inhibitor ribociclib (LEE011) alone and in dual-targeting approaches demonstrates antitumoral efficacy in neuroendocrine tumors in vitro","volume":"106","author":"Aristizabal Prada","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.clcc.2022.08.003_bib0093","series-title":"NANETS 2018 Symposium Abstracts","article-title":"A pilot study of the cyclin dependent kinases 4, 6 inhibitor ribociclib in patients with foregut neuroendocrine tumors","author":"Dasari","year":"2018"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002822000883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002822000883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:10:05Z","timestamp":1761520205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002822000883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1533002822000883"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2022.08.003","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Therapy for Pancreatic Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}